leisure time -WSS

leisure time

author：fashion 2025-09-02 11:45:21 - browse：98234

Illustration of doctor with an computer text bubble for a face for a story on Chat GPT and AI – health tech coverage from STAT — Mike Reddy for STAT

Health care companies are racing to incorporate generative AI tools into their product pipelines and IT systems after the technology displayed an ability to perform many tasks faster, cheaper — and sometimes better — than humans.

But the rush to harness the power of so-called large language models, which are trained on vast troves of data, is outpacing efforts to assess their value. AI experts are still trying to understand, and explain, how and why they work better than prior systems, and what blind spots might undermine their usefulness in medicine.

It remains unclear, for example, how well these models will perform, and what privacy and ethical quandaries will arise, when they’re exposed to new types of data, such as genetic sequences, CT scans, and electronic health records. Even knowing exactly how much data must be fed into a model to achieve peak performance on a given task is still largely guesswork.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： How doctors’ personal politics affect patients

WSS

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

CDC Director Mandy Cohen on transparency, trust, and health

STAT Readout Newsletter: Biotech news today

STAT Summit: Meghan O’Rourke on making chronic illness visible

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Cassava Sciences’ Alzheimer’s clinical trials should be halted

leisure time

leisure time

focus

Cancer drug shortages should be causing more outrage

Rise in cancer among younger people worries and puzzles doctors

Walensky prepares to leave CDC — and Congress — behind

How AI can help patients find reliable information about doctors

Sports medicine is finally prioritizing gender equality

Dems pitch expanding Medicare power to negotiate drug prices

Bright Health sells Medicare Advantage business to Molina

STAT Readout: Friday, Oct. 20 biotech updates

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Roche acquires Telavant from Roivant, adding experimental IBD treatment

focus

Democrats decry new health bill for going easy on private equity

Dems pitch expanding Medicare power to negotiate drug prices

UHS says company favors patients whose insurance pays more

UHS says company favors patients whose insurance pays more

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Roivant's CEO is a star, but biotech's black hole persists

knowledge

Wikipedia

leisure time

hotspot